Peptidome characterization of ovarian cancer serum and the identification of tumor suppressive peptide ZYX36-58

Wang, Xusu; Liu, Guangquan; Sheng, Na; Zhang, Mi; Pan, Xinxing; Liu, Siyu; Huang, Ke; Cong, Yu Sheng; Xu, Qing; Jia, Xuemei; Xu, Juan

doi:10.21037/atm-20-2018

Cited by 6 publications

(5 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After separation by LC, the purified peptides were transported to an Orbitrap Fusion Lumos (Thermo Fisher Scientific) for DDA (data‐dependent acquisition). Then, gene ontology, with reference to the Kyoto Encyclopedia of Genes and Genomes pathway database, was performed as previously described 25 . By using mass spectrometry, we identified the free peptides that exist in the ovary of patients with or without POF, and the peptides were verified by database alignment using the database of the corresponding species (Human SwissProt database).…”

Section: Methodsmentioning

confidence: 99%

“…The gels were then stained with silver to reveal all the proteins in each sample using a Pierce Silver Staining Kit (24600, Thermo Fisher Scientific) according to the manufacturer's instructions. The bands in the gels were removed and cut into colloidal particles of about 1 mm in diameter, and the proteins were extracted as previously described 25 …”

Section: Methodsmentioning

confidence: 99%

“…The bands in the gels were removed and cut into colloidal particles of about 1 mm in diameter, and the proteins were extracted as previously described. 25…”

Section: Peptide Pull-down and Silver Stainingmentioning

confidence: 99%

See 2 more Smart Citations

The novel peptide PFAP1 promotes primordial follicle activation by binding to MCM5

et al. 2023

Self Cite

View full text Add to dashboard Cite

Premature ovarian failure (POF) is a complication of ovarian dysfunction resulting from the depletion or dysfunction of primordial follicles (PFs) in the ovaries.However, residual follicles that have the potential to be activated are present in POF or aged women. Little is known about the mechanisms by which the remaining dormant PFs in POF patients are activated. Using mass spectrometry, we screened differentially generated peptides extracted from the ovarian cortical tissue biopsies of patients with or without POF, during which we identified PFAP1, a peptide that significantly promoted the activation of PFs in the ovaries of 3 dpp mice in vitro. PFAP1 reversed age-related fertility damage in vivo to a certain extent, promoted estrogen (E2) and anti-mullerian hormone (AMH) production (p < .05), and decreased the levels of follicle-stimulating hormone (FSH) (p < .05).In newborn mouse ovaries, PFAP1 could bind to the protein minichromosome maintenance protein 5 (MCM5) and inhibit its ubiquitination and degradation.In addition, PFAP1 promoted the proliferation of GCs, probably by regulating the function and production of MCM5. In conclusion, PFAP1 could promote the activation of PFs in the ovaries of newborn mice, partially restore the ovarian function of aged mice, and increase the proliferation of primary granulosa cells (GCs) by regulating the function of MCM5. PFAP1 is a promising novel peptide that may be developed into a new therapeutic agent for POF and other ovarian diseases.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

The novel peptide PFAP1 promotes primordial follicle activation by binding to MCM5

et al. 2023

Self Cite

View full text Add to dashboard Cite

show abstract

“…21 The ZYX 36-58 peptide inhibited invasion and migration and improved apoptosis of OC cells. 22 In recent years, plasma peptides [23][24][25] or peptides in human biofluids 26 have been found to be associated with cancer and may play a pivotal role in cancer development, including metastasis. Thus, peptides secreted from the omentum may play an important role in OC metastasis.…”

Section: Introductionmentioning

confidence: 99%

Analysis of the Secreted Peptidome from Omental Adipose Tissue in High-Grade Serous Ovarian Cancer

Pan

Xu²,

Dai³

et al. 2023

Crit Rev Eukaryot Gene Expr

Self Cite

View full text Add to dashboard Cite

High-grade serous ovarian cancer (HGSOC) is a preferential omental metastasis malignancy. Since omental adipose tissue is an endocrine organ, we used liquid chromatography tandem mass spectrometry (LC-MS/MS) to compare the peptides secreted from omental adipose tissues of HGSOC and benign serous ovarian cysts (BSOC). Among the differentially secreted peptides, we detected 58 upregulated peptides, 197 downregulated peptides, 24 peptides that were only in the HGSOC group and 20 peptides that were only in the BSOC group (absolute fold change ≥ 2 and <i>P</i> < 0.05). Then, the basic characteristics of the differential peptides were analyzed, such as lengths, molecular weights, isoelectric points, and cleavage sites. Furthermore, we summarized the possible functions according to the precursor protein functions of the differentially expressed peptides by Gene Ontology (GO) analysis with the Annotation, Visualization, and Integrated Discovery (DAVID) database and canonical pathway analysis with IPA. For the GO analysis, the differentially secreted peptides were mainly associated with binding in molecular function and cellular processes in biology process. For the canonical pathways, the differentially secreted peptides were related to calcium signaling, protein kinase A signaling, and integrin-linked kinase (ILK) signaling. We also identified 67 differentially secreted peptides that located in the functional domains of the precursor proteins. These functional domains were mainly related to energy metabolism and immunoregulation. Our study might provide drugs that could potentially treat HGSOC or omental metastases of HGSOC cells.

show abstract

“…[1] OC is the leading cause of mortality among patients bearing gynaecological cancers and the majority of patients are diagnosed in advanced stages. [2] At present, the standard first-line treatment for OC is cytoreductive surgery followed by platinum-based combination chemotherapy, which is basically the same as fallopian tube or primary peritoneal cancer. [3][4][5] Malignant ascites refers to peritoneal effusion caused by primary peritoneal or other malignant tumors that metastasize to the peritoneum.…”

Section: Introductionmentioning

confidence: 99%

A single-center randomized controlled study of intraperitoneal hyperthermic chemoperfusion in combination of recombinant human tumor necrosis factor (TNF) in treatment of malignant ascites caused by advanced abdominal cancers

Wu¹,

Zhu²,

Meng³

et al. 2022

Medicine

View full text Add to dashboard Cite

Introduction: Malignant peritoneal effusion is a common complication of advanced malignancies, which has a poor prognosis for patients. Hyperthermic intraperitoneal chemotherapy (HIPEC) has been widely used in the treatment of advanced gynecological tumors, especially ovarian cancer (OC). Relative studies have indicated that HIPEC allows for direct exposure of tumor cells to high peritoneal concentrations of cytotoxic drugs without increasing systemic toxicity compared with intravenous treatment. Recombinant human tumor necrosis factor for injection (rmhTNF-NC) is a safely tolerated immunotherapeutic drug that has becoming a mainstay of treatment for malignant effusions. Currently, a prospective study is required to determining the efficacy of rmhTNF-NC plus cisplatin for the treatment of malignant peritoneal effusion for OC. Methods: Design and setting: This is a single-center, open trial will be performed in Zhongshan Affiliated Hospital, Guangzhou University of Chinese Medicine. Participants: Eligible patients will be those with advanced gynecologic cancers and who would be suitable for HIPEC. Intervention and Control: HIPEC with cisplatin and intraperitoneal perfusion with rmhTNF-NC. Co-interventions: Further chemotherapy will be offered to patients as per current practice. Outcomes Pilot study: Patients and clinicians’ acceptability of the trial to assist in optimization of recruitment. Primary outcome: One-year overall survival (OS). Secondary outcomes: Progression-free survival (PFS), adverse events. Follow-up: One-year follow-up for OS. Sample size: Twenty patients to demonstrate therapeutic effect of peritoneal effusion caused by OC. Discussion: This trial will determine the effectiveness of HIPEC with cisplatin and intraperitoneal perfusion with rmhTNF-NC for advanced gynecologic cancers, and guide the optimal treatment for these patients.

show abstract

Peptidome characterization of ovarian cancer serum and the identification of tumor suppressive peptide ZYX36-58

Cited by 6 publications

References 49 publications

The novel peptide PFAP1 promotes primordial follicle activation by binding to MCM5

The novel peptide PFAP1 promotes primordial follicle activation by binding to MCM5

Analysis of the Secreted Peptidome from Omental Adipose Tissue in High-Grade Serous Ovarian Cancer

A single-center randomized controlled study of intraperitoneal hyperthermic chemoperfusion in combination of recombinant human tumor necrosis factor (TNF) in treatment of malignant ascites caused by advanced abdominal cancers

Contact Info

Product

Resources

About